4,595 Shares in Vericel Co. (NASDAQ:VCEL) Acquired by Cibc World Markets Corp

Cibc World Markets Corp bought a new stake in Vericel Co. (NASDAQ:VCEL) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 4,595 shares of the biotechnology company’s stock, valued at approximately $252,000.

Other large investors also recently added to or reduced their stakes in the company. Wellington Management Group LLP grew its stake in Vericel by 214.0% during the 3rd quarter. Wellington Management Group LLP now owns 587,857 shares of the biotechnology company’s stock worth $24,837,000 after purchasing an additional 400,667 shares in the last quarter. Stifel Financial Corp lifted its stake in shares of Vericel by 40.0% in the 3rd quarter. Stifel Financial Corp now owns 28,073 shares of the biotechnology company’s stock worth $1,186,000 after acquiring an additional 8,020 shares during the period. Geode Capital Management LLC lifted its holdings in Vericel by 0.8% in the third quarter. Geode Capital Management LLC now owns 1,154,053 shares of the biotechnology company’s stock valued at $48,768,000 after acquiring an additional 9,613 shares during the period. Louisiana State Employees Retirement System raised its holdings in Vericel by 0.8% during the fourth quarter. Louisiana State Employees Retirement System now owns 23,900 shares of the biotechnology company’s stock worth $1,312,000 after purchasing an additional 200 shares during the last quarter. Finally, Intech Investment Management LLC purchased a new position in shares of Vericel during the third quarter valued at approximately $563,000.

Analyst Ratings Changes

A number of analysts have recently issued reports on the company. Truist Financial reiterated a “buy” rating and set a $61.00 target price (down previously from $67.00) on shares of Vericel in a report on Monday, March 3rd. HC Wainwright reissued a “buy” rating and set a $60.00 price target on shares of Vericel in a report on Friday, February 28th. StockNews.com raised Vericel from a “sell” rating to a “hold” rating in a research note on Saturday, March 8th. Canaccord Genuity Group boosted their target price on Vericel from $64.00 to $67.00 and gave the stock a “buy” rating in a report on Monday, February 3rd. Finally, BTIG Research lifted their target price on Vericel from $56.00 to $66.00 and gave the stock a “buy” rating in a report on Tuesday, November 26th. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $62.29.

Insider Activity at Vericel

In other news, CEO Dominick Colangelo sold 26,592 shares of the company’s stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $45.78, for a total value of $1,217,381.76. Following the sale, the chief executive officer now owns 259,997 shares of the company’s stock, valued at approximately $11,902,662.66. This represents a 9.28 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Jonathan Siegal sold 3,908 shares of Vericel stock in a transaction dated Tuesday, January 28th. The shares were sold at an average price of $61.99, for a total transaction of $242,256.92. Following the transaction, the insider now directly owns 1,206 shares of the company’s stock, valued at $74,759.94. This represents a 76.42 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 34,092 shares of company stock valued at $1,683,582 in the last 90 days. 5.20% of the stock is owned by corporate insiders.

Vericel Stock Up 0.0 %

Shares of VCEL opened at $47.96 on Wednesday. The stock’s 50-day moving average price is $53.95 and its 200 day moving average price is $51.75. The firm has a market capitalization of $2.40 billion, a price-to-earnings ratio of 799.47 and a beta of 1.78. Vericel Co. has a 12-month low of $39.12 and a 12-month high of $63.00.

Vericel Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.